Stock Ratings / Health Care / CCCC / dividends

EDIT (29) ALLO (33) AUTL (21) PROK (35) ⌘ Pro Terminal →

C4 Therapeutics Inc. (CCCC) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.37 +2.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.38

C4 Therapeutics Inc. (CCCC) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $414.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CCCC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CCCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, C4 Therapeutics Inc. (NASDAQ: CCCC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.37 (+2.12% 1D, market cap $414.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CCCC ranks #828 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CCCC compare to EDIT and ALLO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CCCC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $410.1M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $407.7M). Among the 5-stock peer group, CCCC leads on earnings multiple (N/A) while CCCC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CCCC?

▼

Per CCCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662579), C4 Therapeutics Inc. generated $35.9M in revenue (+1.0% YoY), -$105.0M in net income, and -$99.3M in free cash flow against $359.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.38 (+0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CCCC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY CCCC SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (41% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (24% of score)

FRED Regime × Technicals: 48% of 52W Range • RSI-14 at 56.6 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.78+13.7% Next Q

Q2 (-2Q)

Grade E$3.16+1.6% Next Q

Q3 (-1Q)

Grade E$3.21+5% Next Q

Current

Grade E$3.37-9.8% Hist 90D α

Trajectory: E (21) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CCCC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CCCC currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.29) and Max Pain ($3.54) forces dealer call-delta covering toward $5.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CCCC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CCCC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CCCC)

✓Walkthrough of CCCC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CCCC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.86%⚡ TESTING RESISTANCE

2026-11-03O $3.30H $3.37L $3.30C $3.37VOL 2.35M

RES: $3.46SUP: $2.38SMA50: $3.29SMA200: $3.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CCCC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CCCC Butterfly Map → + Track CCCC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CCCC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CCCC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CCCC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CCCC)

Health Care Rank #828 of 1016 ⚔️ EDIT vs CCCC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CCCC vs. EDIT, ALLO, AUTL, PROK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, C4 Therapeutics Inc. (CCCC) ranks #828 by composite RQD confidence (29/100, grade E) and #468 by equity capitalization ($414.6M). Within this direct 5-issuer industry benchmark cohort, CCCC leads on earnings valuation at N/A trailing P/E, while CCCC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CCCC at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CCCC ACTIVE C4 Therapeutics Inc.	E	29/100	—	—	-35.0%	+2.12%	$414.6M	Benchmark Subject
EDIT Editas Medicine Inc.	E	29/100	—	—	-35.0%	-8.87%	$410.1M	/edit-vs-cccc →
ALLO Allogene Therapeutics Inc.	E	33/100	—	—	-35.0%	-5.60%	$407.7M	/allo-vs-cccc →
AUTL Autolus Therapeutics plc	E	21/100	—	-27.8%	-35.0%	-3.80%	$404.6M	/autl-vs-cccc →
PROK ProKidney Corp. (Class A)	D-	35/100	—	—	-35.0%	-11.90%	$391.6M	/prok-vs-cccc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001662579

In its most recent audited fiscal period (FY2025, filed 2025-12-31), C4 Therapeutics Inc. (CCCC) reported GAAP revenue of $35.9M (+1.0% vs. FY2024 revenue of $35.6M , and +73.2% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$98.7M, and free cash flow of -$99.3M (-52.0% YoY). On the balance sheet, CCCC closed FY2025 with $359.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$35.9M	-$105.0M	-$98.7M	-$99.3M	$359.1M	—
FY2024 (FY)	2024-12-31	$35.6M	-$105.3M	-$65.2M	-$65.3M	$349.6M	—
FY2023 (FY)	2023-12-31	$20.8M	-$132.5M	-$106.8M	-$106.8M	—	—

3. CCCC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CCCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CCCC compare to EDIT and ALLO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CCCC?

Where is CCCC trading relative to its 50-day, 200-day, and 52-week technical levels?

CCCC last traded at $3.37 (+2.12% on volume of 2,354,107 shares), positioning the stock +2.43% above its 50-day simple moving average ($3.29) and +4.66% above its 200-day simple moving average ($3.22). Across its 52-week range of $1.69 to $5.17, CCCC sits at the 48.3% percentile with a 14-day RSI of 56.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.95 to $3.79).

CCCC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CCCC pay a dividend and is it safe?

C4 Therapeutics Inc. (CCCC) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CCCC RQD Cockpit CCCC 12M Forecast CCCC Earnings & Move CCCC Dividends & DRIP CCCC Insiders & 13F CCCC Whale Options CCCC Profit Sankey CCCC News & Why

Sector Peer Dials

Allogene Therapeutics Inc.

33 /100

AUTL E

Autolus Therapeutics plc

21 /100

PROK D-

ProKidney Corp. (Class A)

35 /100

ZURA E

Zura Bio Limited (Class A)

29 /100

TECX E

Tectonic Therapeutic Inc.

30 /100

CCCC Core Snapshot

Market Cap $414.6M

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield -24.46%

12M Base Price Target $2.93

FREE TRADER TOOLS

Own CCCC Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With CCCC → 🏆 Trade CCCC in $100K Prop Arena →

CCCC Wire

Why It Moved →

Direct Company Event Yahoo Finance • 17h ago

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Peer / Ecosystem Wire Investing.com • 20h ago

JPMorgan initiates C4 Therapeutics stock coverage at Overweight

Direct Company Event Moomoo • 23h ago

C4 Therapeutics(CCCC) Stock Options Chain | Quotes & News

Direct Company Event GuruFocus • 1d ago

CCCC Initiates Coverage On by JP Morgan -- Rating Overweight

Direct Company Event TradingView • 1d ago

CCCC Q3'26 Earnings: revenue estimate is 8.85M USD

ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CCCC — C4 Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:36:54Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CCCC carries an RQD Score of 28, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 2 / 20. Per the RQD rating, ROIC is -35% and FCF yield is -24.46%. This is the weakest pillar and signals that the business is not currently generating returns on capital or free cash flow.
Whale 13F Flow: 10 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar but still sits at half weight.
Insider Conviction: 3 / 20. Per the RQD rating, this pillar draws on SEC Form 4 and Congressional PTR cluster flow, and scores low.
Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted, a neutral-to-weak alignment.
Forensic Balance Sheet: 5 / 20. Per the RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 0.5. The Altman reading is in the distress zone and the Piotroski reading is weak.

For a prospective investor evaluating the stock today, the implication is that the rating's weight rests on cash-generation and forensic balance-sheet weakness rather than on market or sentiment signals. The upside case would have to come from the institutional-flow pillar, which by itself does not offset the negative fundamentals. Any valuation discussion is constrained because the P/E and EV/EBITDA fields are not available in source data. The rating is an analytical framework output, not a recommendation to buy or sell.

Business

C4 Therapeutics Inc. (CCCC) is listed on NASDAQ and operates in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, the market capitalization is $0.4B. Product details, customer base, and revenue model are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$35.9M	$-115.2M	$-105.0M	N/A	$-99.3M	$74.6M	N/A
FY 2024	$35.6M	$-119.6M	$-105.3M	N/A	$-65.3M	$55.5M	N/A
FY 2023	$20.8M	$-139.0M	$-132.5M	N/A	$-106.8M	N/A	N/A

Per the SEC financials, the company reported operating losses across all three listed periods, with operating margin at -60% and net margin at -60% in the market data section. Gross margin is listed as 0%. ROIC is -35%. Per the RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both weak readings. Per the RQD rating, Debt/Equity is 0.5. Cash rose from $55.5M to $74.6M between FY 2024 and FY 2025 while free cash flow remained negative.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines include an Expected to Beat Earnings Estimates report, a JPMorgan initiation of coverage at Overweight, a TradingView note listing Q3'26 revenue estimate as 8.85M USD, and several options and seasonal-chart listings. The coverage initiation is the most concrete catalyst mentioned. The earnings-beat headline is a forward-looking expectation and is not a reported result. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals, so no supply-chain catalysts are identified. Risk watch items include the negative FCF and the Altman distress reading noted in the RQD rating.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The sector and industry classification is the only sector context provided.

Analyst View & Smart Money Ownership

Analyst consensus rating and price targets are not available in source data. Per the analyst data section, no analyst records are provided. Per the holders section, no SEC Form 4, 13F, or Congressional trade records are provided. The news feed references a JPMorgan initiation at Overweight, but no price target or consensus is given.

Open Questions

What is the company's revenue composition and customer concentration, given that revenue is reported but its sources are not described?
What are the reported EPS, total debt, and P/E figures, since these fields are listed as N/A or not available?
What is the cash runway implied by the FY 2025 cash balance of $74.6M against negative free cash flow of $-99.3M?
What is the status of the pipeline and any clinical or regulatory milestones referenced in the catalyst coverage?
What are the analyst price targets and rating distribution, given that the analyst data section is empty?

CCCC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for C4 Therapeutics Inc. (CCCC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CCCC Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 17h ago

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Yahoo Finance report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 20h ago

JPMorgan initiates C4 Therapeutics stock coverage at Overweight

Investing.com report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 23h ago

C4 Therapeutics(CCCC) Stock Options Chain | Quotes & News

Moomoo report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

CCCC Initiates Coverage On by JP Morgan -- Rating Overweight

GuruFocus report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CCCC Q3'26 Earnings: revenue estimate is 8.85M USD

TradingView report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

C4 Therapeutics, Inc. (CCCC) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 1d ago

A tool found compounds for a protein called VAV1. C4 Therapeutics doesn't plan to advance without a partner.

Stock Titan report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

C4 Therapeutics, Inc. (CCCC) Seasonal returns chart

Yahoo Finance UK report covering C4 Therapeutics Inc. (CCCC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CCCC Bull vs. Bear Conversation Board — What's Your Call at $3.37?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CCCC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.90 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CCCC (E • RQD 28/100) a Buy at $3.30?

Welcome to the CCCC (C4 Therapeutics Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.61 (-20.9%)

Spot @ $3.30

Pump the brakes on CCCC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CCCC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless C4 Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.93 (+19.1%)

Spot @ $3.30

CCCC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CCCC, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $3.30 (52-wk range $1.69 - $5.17), any beat on forward guidance forces shorts and underweight funds to chase.